La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Photocure Gestione

Gestione criteri di controllo 1/4

Photocure's Il CEO è Dan Schneider, nominato in Nov2018, ha un mandato di 5.75 anni. possiede direttamente 0.37% delle azioni della società, per un valore di NOK 5.03M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.8 anni e 1.6 anni.

Informazioni chiave

Dan Schneider

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	5.8yrs
Proprietà del CEO	0.4%
Durata media del management	5.8yrs
Durata media del Consiglio di amministrazione	1.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analyst Estimates: Here's What Brokers Think Of Photocure ASA (OB:PHO) After Its Second-Quarter Report

Aug 14

We Think Photocure (OB:PHO) Can Stay On Top Of Its Debt

Aug 12

Do Institutions Own Photocure ASA (OB:PHO) Shares?

Feb 11

Photocure ASA's (OB:PHO) Stock Is Going Strong: Have Financials A Role To Play?

Jan 21

The Photocure (OB:PHO) Share Price Is Up 286% And Shareholders Are Boasting About It

Dec 31

We're Not So Sure You Should Rely on Photocure's (OB:PHO) Statutory Earnings

Dec 09

Is Photocure (OB:PHO) Using Too Much Debt?

Nov 19

AMMINISTRATORE DELEGATO

Dan Schneider

5.8yrs

Mandato

Mr. Daniel Schneider, also known as Dan, joined Photocure ASA since November 2018 and has been President & CEO of PhotoCure ASA since November 1, 2018. He has been Vice President of Sales at Pernix Sleep,...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Daniel Schneider	President & CEO	5.8yrs	Nessun dato	0.37% NOK 5.3m
Erik Dahl	Chief Financial Officer	12.1yrs	Nessun dato	0.12% NOK 1.7m
David Moskowitz	Head of Investor Relations	no data	Nessun dato	Nessun dato
Anja Gossens-von der Heidt	Head of Global Human Resources	no data	Nessun dato	Nessun dato
Anders Neijber	Chief Medical Officer of Global Medical Affairs	2yrs	Nessun dato	Nessun dato
Tolv Hillestad	Group Controller	no data	Nessun dato	Nessun dato

5.8yrs

Durata media

Gestione esperta: Il team dirigenziale di PHO è esperto e expertise (durata media dell'incarico 5.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Johanna Holldack	Independent Director	7.4yrs	Nessun dato	Nessun dato
Neal Shore	Independent Director	no data	Nessun dato	Nessun dato
Dylan Hallerberg	Independent Chairman	1.7yrs	Nessun dato	0.55% NOK 7.9m
Ghizlane Tagmouti	Director	less than a year	Nessun dato	Nessun dato
Malene Brandborg	Independent Director	no data	Nessun dato	Nessun dato

1.7yrs

Durata media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di PHO non è considerato esperto (durata media del mandato 1.6 anni), il che suggerisce un nuovo consiglio.

Photocure Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Photocure ASA Announces Board Appointments

Photocure ASA Announces Change of Board Composition

Director recently bought kr6.5m worth of stock

Insufficient new directors

Photocure ASA Appoints Anders Neijber as Chief Medical Officer, Global Medical Affairs and Clinical Development

President & CEO exercised options to buy kr10m worth of stock.

Recent updates

We Think Photocure's (OB:PHO) Robust Earnings Are Conservative

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates increase from loss to kr0.019 profit

Photocure ASA's (OB:PHO) P/S Still Appears To Be Reasonable

Photocure ASA Announces Board Appointments

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Photocure ASA Reiterates Financial Guidance for the Year 2024

Consensus EPS estimates fall from profit to kr0.58 loss

Photocure ASA Announces Pivotal Trial Results and New Real-World Evidence

Photocure ASA Announces the Publication of the Study Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Consensus EPS estimates increase by 50%, revenue downgraded

Price target decreased by 7.0% to kr86.00

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Forecast breakeven date pushed back to 2025

Photocure ASA to Report Q4, 2023 Results on Feb 21, 2024

Photocure ASA's (OB:PHO) 26% Jump Shows Its Popularity With Investors

Photocure ASA Partner Asieris Announces New Drug Application Acceptance for Regulatory Review of Hexvix in China

Third quarter 2023 earnings released: kr0.18 loss per share (vs kr0.37 loss in 3Q 2022)

Photocure ASA Announces Change of Board Composition

Director recently bought kr6.5m worth of stock

Potential Upside For Photocure ASA (OB:PHO) Not Without Risk

Price target decreased by 10.0% to kr90.00

Photocure Partner Asieris Confirms Hexvix Phase III Clinical Trial in China Meets Endpoint

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Photocure Partner Asieris Announces Completion of Enrollment for Hexvix Phase III Clinical Trial in China

Insufficient new directors

Consensus estimates of losses per share improve by 15%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Time To Worry? Analysts Just Downgraded Their Photocure ASA (OB:PHO) Outlook

Price target decreased by 7.7% to kr120

Forecast breakeven date pushed back to 2024

Full year 2022 earnings released: kr2.66 loss per share (vs kr1.15 loss in FY 2021)

Photocure Asa Announces Clinical Data Presented At ASCO GU Demonstrates Reduced Risk of Recurrence in Non-Muscle Invasive Bladder Cancer with the Use of BLC

Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week

Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week

Photocure ASA to Report First Half, 2023 Results on Aug 09, 2023

Photocure ASA Announces New Evidence Presented At the 22nd Annual Society of Urologic Oncology Meeting Demonstrating That Blue Light Cystoscopy

Price target decreased to kr125

Third quarter 2022 earnings released: kr0.37 loss per share (vs kr0.27 loss in 3Q 2021)

Photocure Asa Announces Data Presented At the International Bladder Cancer Network (Ibcn) Meeting Demonstrate A Reduction in the Risk of Recurrence with the Use of Blc

PPhotocure ASA Announces the Commercial Availability of Karl Storz's New Blue Light System in the U.S

Photocure ASA Publishes First Results from Laser III Clinical Study in Medical Journal, European Urology

Photocure ASA Announces Continue E Supporting the Global Launch Activities of the New and Improved Blue Light Cystoscopy

Photocure ASA Appoints Anders Neijber as Chief Medical Officer, Global Medical Affairs and Clinical Development

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to kr135

Photocure Asa Provides Update on Anticipated Commercial Availability of Karl Storz's New Blue Light System in the United States

Photocure ASA Presents Positive Data from the Danish National Patient Registry at the 2022 NordUrologisk Forening (NUF) Congongress in Helsinki

Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on April 28, 2022.

President & CEO exercised options to buy kr10m worth of stock.

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Photocure Announces Endotherapeutics Group as New Commercial Partner for Hexvix in Australia & New Zealand

Photocure ASA Announces the Publication of Pre-Clinical Study Results Supporting the Anti-tumor Effect of Hexaminolevulinate with Blue Light in Bladder Cancer model

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Photocure ASA Receives FDA Approval for Use in NMIBC in the U.S

Consensus EPS estimates fall to -kr0.53

Third quarter 2021 earnings released: kr0.27 loss per share (vs kr0.23 loss in 3Q 2020)

Insider exercised options to buy kr2.8m worth of stock.

Consensus EPS estimates fall to -kr0.53

Analyst Estimates: Here's What Brokers Think Of Photocure ASA (OB:PHO) After Its Second-Quarter Report

We Think Photocure (OB:PHO) Can Stay On Top Of Its Debt

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.37 loss in 2Q 2020)

Photocure ASA Announces the Publication of a Study in the Journal Urologic Oncology

Asieris Announces First Patient Administration in Europe within the Phase III Clinical Trial for APL-1702 (Cevira)

President & CEO exercised options to buy kr2.8m worth of stock.

Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on June 10, 2020.

Photocure ASA Suspends Guidance for 2023

Analysts lower EPS estimates to kr0.94